medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2013-12-84-89medsovet-1169Research ArticleРЕВМАТОЛОГИЯRHEUMATOLOGYАмтолметин гуацил. Можно ли создать улучшенный НПВП?Amtolmetin guacil: is it possible to develop an "advanced" NSAID?КаратеевА. Е.KarateyevA. E.noemail@neicon.ruФГБУ «НИИР им. В.А. Насоновой» РАМНРоссияResearch Institute of Rheumatology named after V.A. Nasonova RAMSRussian Federation2013301220130128489Copyright © Каратеев А.Е., 20132013Каратеев А.Е.Karateyev A.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1169

НПВП - важнейший инструмент лечения острой и контроля хронической боли. Однако НПВП могут вызывать серьезные осложнения со стороны ЖКТ и сердечно-сосудистой системы. Фармакологи неоднократно предпринимали попытки создать «улучшенные» НПВП, не оказывающие повреждающего действия на ЖКТ. К таким препаратам относятся коксибы, НПВП в комбинации с гастропротекторами (мизопростол, Н2-блокаторы, ИПП), ЦОГ-2/ЛОГ-2 ингибиторы, CINOD. Все эти препараты имеют свои недостатки, некоторые из них используются в практике, другие остались на уровне научных разработок или уже вышли из клинической практики. Амтолметин гуацил - новый «улучшенный» НПВП, созданный на основе неселективного НПВП толметина и обладающий комплексом гастропротективных свойств. Главным из них является повышение концентрации NO в слизистой ЖКТ. В статье рассмотрен механизм действия нового препарата, представлены данные его лабораторных и клинических испытаний.

NSAID is a key element in the treatment of acute pain and management of chronic pain. However, NSAIDs may cause serious complications in the gastrointestinal tract and the cardiovascular system. Pharmacologists have been trying to develop an "advanced" NSAID which does not affect the gastrointestinal tract, including coxibs, NSAIDs in combination with gastroprotective agents (misoprostol, H2 blockers, PPI), COX-2/LOX-2 inhibitors, and CINOD. All of these drugs have their limitations, some of them are being used, while others remained in the research phase or were ousted from clinical practice. Amtolmetin guacil is a new "advanced" NSAID based on the non-selective NSAID tolmetin, which posesses a number of gastroprotective attributes. It is specific for being able to increase the NO concentration in the gastrointestinal mucosa. The article describes the mechanism of action of the new drug, and shares the results of laboratory and clinical trials.

нестероидные противовоспалительные препаратыдоноры оксида азотатолметинамтолметин гуацилгастропротективный эффектnonsteroidal anti-inflammatory drugsnitric oxide donorstolmetinamtolmetin guacilgastroprotective effectReferencesНасонов Е.Л. Анальгетическая терапия в ревматологии: путешествие между Сциллой и Харибдой // Клин. фармакол. и терапия. 2003. №12(1). С. 64-69.Насонов Е.Л. Анальгетическая терапия в ревматологии: путешествие между Сциллой и Харибдой // Клин. фармакол. и терапия. 2003. №12(1). С. 64-69.Боль (практическое руководство для врачей) / под ред. Н.Н. Яхно, М.Л. Кукушкина. М.: Издательство РАМН, 2012.Боль (практическое руководство для врачей) / под ред. Н.Н. Яхно, М.Л. Кукушкина. М.: Издательство РАМН, 2012.Lee Y. Effect and treatment of chronic pain in inflammatory arthritis // Curr. Rheumatol. Rep. 2013. №15(1). Р. 300. van de Laar M. Pergolizzi J., Mellinghoff H. et al. Pain Treatment in Arthritis-Related Pain: Beyond NSAIDs // The Open Rheumatology Journal. 2012. №6. Р. 320-330.Lee Y. Effect and treatment of chronic pain in inflammatory arthritis // Curr. Rheumatol. Rep. 2013. №15(1). Р. 300. van de Laar M. Pergolizzi J., Mellinghoff H. et al. Pain Treatment in Arthritis-Related Pain: Beyond NSAIDs // The Open Rheumatology Journal. 2012. №6. Р. 320-330.Fiorucci S., Distrutti E. COXIBs, CINODs and H2S-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs // Curr. Med. Chem. 2011. №18(23). Р. 3494-3505.Fiorucci S., Distrutti E. COXIBs, CINODs and H2S-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs // Curr. Med. Chem. 2011. №18(23). Р. 3494-3505.Hunt R., Harper S., Watson D. et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events // Am. J. Gastroenterol. 2003. №98(8). Р 1725-1733.Hunt R., Harper S., Watson D. et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events // Am. J. Gastroenterol. 2003. №98(8). Р 1725-1733.Laine L., Curtis S.P., Cryer B. et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with oste-oarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison // Lancet. 2007. №369. Р. 465-473.Laine L., Curtis S.P., Cryer B. et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with oste-oarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison // Lancet. 2007. №369. Р. 465-473.Silverstein F. New strategies for the prevention of serious upper GI complication from NSAIDs: lessons from the MUCOSA trial // New stand. Arth. Care. 1996. №5. Р. 2-6.Silverstein F. New strategies for the prevention of serious upper GI complication from NSAIDs: lessons from the MUCOSA trial // New stand. Arth. Care. 1996. №5. Р. 2-6.Acevedo E., Castaneda O., Ugaz M. et al. Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis. Scand // J. Rheumatol. 2001. №30. P. 19-24.Acevedo E., Castaneda O., Ugaz M. et al. Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis. Scand // J. Rheumatol. 2001. №30. P. 19-24.Roberts D., Miner P. Safety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease // Drug. Healthc. And Patient. Saf. 2011. №3. P. 1-8.Roberts D., Miner P. Safety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease // Drug. Healthc. And Patient. Saf. 2011. №3. P. 1-8.Gigante A., Tagarro I. Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on keto-profen/omeprazole // Clin. Drug. Investig. 2012. №32(4). P. 221-233.Gigante A., Tagarro I. Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on keto-profen/omeprazole // Clin. Drug. Investig. 2012. №32(4). P. 221-233.Bello A. DUEXIS® (ibuprofen 800 mg, famotidine 26.6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug // Ther. Adv. Musculoskelet. Dis. 2012. №4(5). P. 327–339.Bello A. DUEXIS® (ibuprofen 800 mg, famotidine 26.6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug // Ther. Adv. Musculoskelet. Dis. 2012. №4(5). P. 327–339.Kulkarni S.K., Singh V.P. Licofelone: the answer to unmet needs in osteoarthritis therapy? // Curr. Rheumatol. Rep. 2008. №10(1). P. 43–48.Kulkarni S.K., Singh V.P. Licofelone: the answer to unmet needs in osteoarthritis therapy? // Curr. Rheumatol. Rep. 2008. №10(1). P. 43–48.Lanas A. Role of nitric oxide in the gastrointestinal tract // Arthritis Research & Therapy. 2008. №10. Suppl. 2. P. 4. doi:10.1186/ar2465.Lanas A. Role of nitric oxide in the gastrointestinal tract // Arthritis Research & Therapy. 2008. №10. Suppl. 2. P. 4. doi:10.1186/ar2465.Keeble J., Moore P. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs // British Journal of Pharmacology. 2002. №137. P. 295–310.Keeble J., Moore P. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs // British Journal of Pharmacology. 2002. №137. P. 295–310.Lanas A., García-Rodríguez L.A., Arroyo M.T. et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants // Am. J. Gastroenterol. 2007. №102(3). P. 507–515.Lanas A., García-Rodríguez L.A., Arroyo M.T. et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants // Am. J. Gastroenterol. 2007. №102(3). P. 507–515.Lohmander L.S., McKeith D., Svensson O. et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis // Ann. Rheum. Dis. 2005. №64. P. 449–456.Lohmander L.S., McKeith D., Svensson O. et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis // Ann. Rheum. Dis. 2005. №64. P. 449–456.Cordrey LJ. Tolmetin sodium, a new anti-arthritis drug: double-blind and long-term studies // Journal of the American Geriatrics Society. 1976. №24(10). P. 440–446.Cordrey LJ. Tolmetin sodium, a new anti-arthritis drug: double-blind and long-term studies // Journal of the American Geriatrics Society. 1976. №24(10). P. 440–446.AHFS Drug Information 2007. McEvoy G.K., ed. Tolmetin. Bethesda, MD // American Society of Health-System Pharmacists. 2007. P. 2118–2122.AHFS Drug Information 2007. McEvoy G.K., ed. Tolmetin. Bethesda, MD // American Society of Health-System Pharmacists. 2007. P. 2118–2122.Coruzzi G., Coppelli G., Spaggiari S. et al. Gastroprotective effects of amtolmetin guacyl: a new non-steroidal anti-inflammatory drug that activates inducible aastric nitric oxide svnthase // Dig Liver Dis. 2002. №34(6). 403–410.Coruzzi G., Coppelli G., Spaggiari S. et al. Gastroprotective effects of amtolmetin guacyl: a new non-steroidal anti-inflammatory drug that activates inducible aastric nitric oxide svnthase // Dig Liver Dis. 2002. №34(6). 403–410.Tubaro E., Belogi L., Mezzadri C.M. The mechanism of action of amtolmetin guacyl, a new gastroprotective nonsteroidal anti-inflammatory drug // European Journal of Pharmacology. 2000. №387. P. 233–244.Tubaro E., Belogi L., Mezzadri C.M. The mechanism of action of amtolmetin guacyl, a new gastroprotective nonsteroidal anti-inflammatory drug // European Journal of Pharmacology. 2000. №387. P. 233–244.Morini G., Guaita E., Lazzaretti M. et al. Morphological features of rat gastric mucosa after acute and chronic treatment with amtolmetin guacyl: comparison with non-selective and COX-2-selective NSAIDs // Digestion. 2003. №68(2–3). P. 124–132.Morini G., Guaita E., Lazzaretti M. et al. Morphological features of rat gastric mucosa after acute and chronic treatment with amtolmetin guacyl: comparison with non-selective and COX-2-selective NSAIDs // Digestion. 2003. №68(2–3). P. 124–132.Riezzo G., Chiloiro M., Montanaro S. Protective effect of amtolmetin guacyl versus placebo diclofenac and misoprostol in healthy volunteers evaluated as gastric electrical activity in alcohol-induced stomach damage // Dig Dis Sci. 2001. №46(8). P. 1797–1804.Riezzo G., Chiloiro M., Montanaro S. Protective effect of amtolmetin guacyl versus placebo diclofenac and misoprostol in healthy volunteers evaluated as gastric electrical activity in alcohol-induced stomach damage // Dig Dis Sci. 2001. №46(8). P. 1797–1804.Tavella A., Ursini G. A clinical study on the anti-inflammatory activity and gastrointestinal tolerability of amtolmetin guacyl, a new NSAID, compared with diclofenac in aged patients with osteoarticular diseases. [Article in Italian] // Clin. Ter. 1997. №148(11). P. 543–548.Tavella A., Ursini G. A clinical study on the anti-inflammatory activity and gastrointestinal tolerability of amtolmetin guacyl, a new NSAID, compared with diclofenac in aged patients with osteoarticular diseases. [Article in Italian] // Clin. Ter. 1997. №148(11). P. 543–548.Marcolongo R., Frediani B., Biasi G. et al. A Meta-Analysis of the Tolerability of Amtolmetin Guacil, a Novel, Effective Nonsteroidal Anti-Inflammatory Drug, Compared with Established Agents // Clin. Drug. Invest. 1999. №17(2). P. 89–96.Marcolongo R., Frediani B., Biasi G. et al. A Meta-Analysis of the Tolerability of Amtolmetin Guacil, a Novel, Effective Nonsteroidal Anti-Inflammatory Drug, Compared with Established Agents // Clin. Drug. Invest. 1999. №17(2). P. 89–96.Jajić Z., Malaise M., Nekam K. et al. Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis // Clin. Exp. Rheumatol. 2005. №23(6). P. 809–818.Jajić Z., Malaise M., Nekam K. et al. Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis // Clin. Exp. Rheumatol. 2005. №23(6). P. 809–818.Belisari A., Mantovani L. Cost-Benefit Analysis of Amtolmetin-Guacil // Clin. Drug. Invest. 2001.Belisari A., Mantovani L. Cost-Benefit Analysis of Amtolmetin-Guacil // Clin. Drug. Invest. 2001.

The authors declare that there are no conflicts of interest present.